Mechanism and research progress of antibody-drug conjugate in the treatment of HER-2 positive breast cancer
The diagnosis and treatment of human epidermal growth factor receptor 2(HER-2)-positive breast cancer has always been a research hotspot in the field of breast cancer.The successive advent of monoclonal antibody drugs and small molecule tyrosine kinase inhibitors has greatly improved the prognosis of patients with HER-2 positive breast cancer.However,behind the excellent efficacy,targeted drugs are also facing major problems such as multi-drug resistance and cardiotoxicity.In recent years,as HER-2-positive breast cancer has entered the era of"precise classification and precise stratification",antibody-drug conjugate(ADC)has become one of the hot areas of precise treatment for cancer patients.ADC binds target-specific monoclonal antibodies to highly cytotoxic drugs through a specific linker,which has a highly specific killing effect on tumor cells.This article reviews the mechanism of ADC and its research progress in HER-2 positive breast cancer.
antibody-drug conjugateargeted therapyhuman epidermal growth factor receptor-2breast cancer
万方数据
维普
